Skip to content


Ocrevus (ocrelizumab) is an antibody pharmaceutical. Ocrelizumab was first approved as Ocrevus on 2017-03-28. It is used to treat multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against B-lymphocyte antigen CD20.
Trade Name Ocrevus
Common Name Ocrelizumab
Indication multiple sclerosis
Drug Class Monoclonal antibodies: humanized, immunomodulating
Get full access now